Cellebrite DI (CLBT) Liabilities and Shareholders Equity (2020 - 2025)

Cellebrite DI's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $938.9 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 35.95% year-over-year to $938.9 million; the TTM figure through Dec 2025 stood at $3.3 billion (up 35.96% YoY), while the FY2025 annual figure was $938.9 million, up 35.95% from the prior year.
• Liabilities and Shareholders Equity was $938.9 million for Q4 2025 at Cellebrite DI, up from $834.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $938.9 million in Q4 2025 to a low of $315.1 million in Q3 2021.
• Historically, Liabilities and Shareholders Equity has averaged $532.5 million across 5 years, with a median of $503.0 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Liabilities and Shareholders Equity dropped 6.75% in 2021, then soared 41.47% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $339.8 million in 2021, then climbed by 18.69% to $403.3 million in 2022, then soared by 32.13% to $532.9 million in 2023, then climbed by 29.59% to $690.6 million in 2024, then jumped by 35.95% to $938.9 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $938.9 million (Q4 2025), $834.3 million (Q3 2025), and $787.4 million (Q2 2025), per Business Quant data.